glycation

Gemigliptin Tartrate (LC15-0444 tartrate) is a highly selective, reversible and competitive inhibitor of dipeptidyl peptidase-4 (DPP-4). It has an IC50 of 10.3 nM for human recombinant DPP-4. Gemigliptin tartrate exhibits potent anti-glycation properties.

Ipriflavone (Osteofix) (Osteofix) is a feed additive and a catabolic agent. It is used to inhibit bone resorption.

Azeliragon (TTP488) is an antagonist at the Receptor for Advanced Glycation End products; is evaluated as a potential treatment for patients with mild-to-moderate Alzheimer_acute_s disease (AD).

FPS-ZM1 is a high-affinity, RAGE-specific inhibitor that obstructs Aβ binding to the V domain of RAGE.

4'-Methoxyresveratrol (4'-O-Methylresveratrol) is a natural product from the roots of *Rheum palmatum* L., with significant hypoglycemic, anti-inflammatory, and antioxidant effects. 4'-Methoxyresveratrol alleviates AGE-induced inflammation by suppressing RAGE-mediated MAPK/NF-κB signaling pathway and NLRP3 inflammasome activation.

Glycation-IN-1 (Compound 3) is an inhibitor of the glycosylation reaction, effectively suppressing the synthesis of the initial, intermediate, and final products of glycation reactions. It is applicable in research on various chronic diseases, including diabetes, immune inflammation, cardiovascular diseases, and neurodegenerative disorders.

Advanced glycation end products are the outcome of non-enzymatic glycation reactions involving biomolecules such as proteins, lipids, nucleic acids, and reducing sugars. Advanced glycation end products are frequently employed in investigating pathological mechanisms associated with diabetes, ageing, and chronic diseases.

Poliumoside is a natural compound which exhibits significant inhibition of advanced glycation end product formation with IC50 value of 4.6-25.7 μM, it also exhibits great inhibitory effects on rat lens aldose reductase with IC50 values of 0.85 μM.Poliumos

Cassiaside C (Toralactone 9-O-β-D-gentiobioside), a naphthopyrone extracted from Cassia tora seeds, demonstrates in vitro inhibitory activity against the formation of advanced glycation end products (AGE).

Pedaliin is a flavonoid extracted from the above-ground parts of sesame (Sesamum indicum L) and the Tibetan medicine Dracocephalum tanguticum Maxim.Pedaliin has shown antioxidant and anticancer effects against colon cancer in vitro, and can be used in the study of cardiovascular diseases.

Sesamoside has antinociceptive activity.

ABR-238901 is an oral, active S100A8/A9 blocker that inhibits the interaction of S100A8/A9 with its receptors RAGE(receptor for advanced glycation end products) and TLR4 (toll-like receptor 4). ABR-238901 has potential as a compound for the treatment of myocardial infarction (MI).

Bromelain is an anti-inflammatory drug derived from pineapple stem. It acts through down-regulation of plasma kininogen, degradation of advanced glycation end-product receptors, inhibition of Prostaglandin E2 expression, and regulation of angiogenic bioma

Anserine (L-Anserine) is a dipeptide containing β-alanine and histidine, which can be found in the skeletal muscle and brain of mammals and birds. Anserine is not cleaved by serum carnosinase and act as biochemical buffers, chelators, antioxidants, and anti-glycation agents. Anserine improves memory functions in Alzheimer's disease (AD)-model mice.

Alagebrium chloride (ALT711) is an advanced glycation end product (AGE) inhibitor that has proven effective in reducing systolic blood pressure and providing therapeutic benefits for patients with diastolic.

DL-Isoleucine exhibits anti-glycation activity in RAW 264.7 cells and exhibits millimolar-level cytotoxicity against SW620, CACO2, SW480, and fibroblast cells.

LR-90, an advanced glycation end product (AGE) inhibitor, is utilized in diabetic animal model research. This compound effectively suppresses inflammatory responses in human monocytes.

Pyridoxylamine (pyridoxamine) is an inhibitor of advanced glycation end production (AGEs) and lipoxidation end products (ALEs).

beta-Glucogallin (beta-Glucogallin) is a selective aldose reductase (AKR1B1) inhibitor with antioxidant, anti-glycation, and anti-inflammatory properties. beta-Glucogallin is a naturally occurring compound derived from Emblica officinalis and is used in diabetes research. Vitamin B3-d4

Fructosyl-lysine is the precursor to glucosepane. Fructosyl-lysine is a lysine–arginine protein cross-link that can be an indicator in diabetes detection. Fructosyl-lysine is an amadori glycation product from the reaction of glucose and lysine by the Maillard reaction.

α-Amylase-IN-12 (Compound 5e) is an α-amylase inhibitor with an IC50 of 0.15 mM, functioning through a mixed inhibition mode. It exhibits an IC50 of 9.40 mM against α-glucosidase. This compound enhances glucose uptake in yeast cells and demonstrates significant anti-glycation activity at high concentrations. α-Amylase-IN-12 is applicable for diabetes research.

RuDiOBn exhibits low antioxidant activity by scavenging DPPH and ABTS free radicals with scavenging rates of 13.2% and 5.9% at a concentration of 100 μg/mL. It inhibits collagen glycation and reduces the formation of advanced glycation end-products (AGE) with an IC50 of 2.45 μg/mL. RuDiOBn also enhances fibroblast proliferation and migration, stimulates collagen synthesis, and aids in skin repair and regeneration while inhibiting collagenase.

Gemigliptin (LC15-0444) tartrate hydrate is a selective, reversible, and competitive inhibitor of dipeptidyl peptidase 4 (DPP-4), with an IC50 value of 10.3 nM for human recombinant DPP-4. It exhibits strong anti-glycation properties and is used in research on advanced glycation end product-related diabetic complications.

Azeliragon is a potent and orally active inhibitor of RAGE (receptor for advanced glycation endproducts), a pattern recognition receptor, which affects the movement of amyloid, an Alzheimer's-associated protein, into the brain.